30.92
-1.94(-5.90%)
Currency In USD
| Previous Close | 32.86 |
| Open | 32.68 |
| Day High | 32.7 |
| Day Low | 30.44 |
| 52-Week High | 36.28 |
| 52-Week Low | 14.32 |
| Volume | 1.89M |
| Average Volume | 1.8M |
| Market Cap | 6.35B |
| PE | -11.16 |
| EPS | -2.77 |
| Moving Average 50 Days | 27.83 |
| Moving Average 200 Days | 23.59 |
| Change | -1.94 |
Immunovant to Report Financial Results for the Third Quarter Ended December 31, 2025, and Provide Business Update on Friday, February 6, 2026
GlobeNewswire Inc.
Jan 23, 2026 10:25 PM GMT
DURHAM, N.C. and NEW YORK, Jan. 23, 2026 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq: IMVT) today announced that it will report its financial results for the third quarter ended December 31, 2025, and provide a business update at 8:00 a.m. ET on Friday,
Immunovant Announces Pricing of $550 Million Common Stock Financing
GlobeNewswire Inc.
Dec 11, 2025 6:29 AM GMT
Funding to provide runway through potential Graves’ Disease commercial launch NEW YORK, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoim
Immunovant to Report Financial Results for the Second Quarter Ended September 30, 2025, and Provide Business Update on Monday, November 10, 2025
GlobeNewswire Inc.
Oct 27, 2025 8:10 PM GMT
NEW YORK, Oct. 27, 2025 (GLOBE NEWSWIRE) -- Immunovant (Nasdaq: IMVT) today announced that it will report its financial results for the second quarter ended September 30, 2025, and provide a business update at 8:00 a.m. ET on Monday, November 10, 2